Too few doctors are prepared to help guide women through menopause. Wen Shen and her compatriots are intent on changing that.

Preserved and frozen in time, the blood and tissue samples stored in Hopkins' biorepositories hold myriad clues to curing disease.

Life is poised to get dramatically better for millions with hepatitis C, thanks to new treatments that promise a more effective cure, without the debilitating side effects.

Strategic plan aims to maintain Hopkins Medicine as international leader.

Johns Hopkins Hospital ranked #1 in the nation.

New blood-ordering guidelines will ensure supply for surgeries where it's needed most.

In June 2012, former dean and CEO Edward Miller retired after more than 15 years at the help of Johns Hopkins Medicine. The magazine sat down with him recently to chat about what he's up to now that he is in control of his own schedule.

A new medical school gets a new curriculum.

Finding holds potential for avoiding joint replacement surgery.

Promising drug clears cancer from bone marrow in hardest to treat cases.

A happier temperament could reduce chance of heart attack.

New stent procedure avoids problem of recurrence.

Option holds promise for many now on waiting list for cadaver liver.

Building the first synthetic yeast genome requires strength in numbers.

Semba's new work catalogs William H. Wilmer's "spectacular" collection of ophthalmology books.

In tracing the bloodlines of medical genetics, Nathaniel Comfort confronts its entanglement with eugenics.

In vitro fertilization was born at Hopkins in the mid-1960s—but the scientists responsible for the achievement wouldn't realize it until years later.  

Lorsch steps up to lead the largest scientific funding agency in the world.

Coordination is key to Cullins' role at Planned Parenthood.

Bach is committed to improving patient outcomes while controlling medical costs.

Why the new MCAT could end up discouraging talented applicants from entering medicine.

Our five-year strategic plan zeroes in on our most valuable resource: people.

Lietman was a builder of programs and people.

Brancati was a widely beloved and admired figure.

Colvin set the course for cancer therapeutics.